The expanded partnership reflects strong demand for Lonza’s global biologics outsourcing platform, spanning diversified clinical and commercial manufacturing programs.
New population-level data reveal unprecedented declines in cervical cancer among vaccinated cohorts, even as vaccination rates begin to slip in some countries.
A €45m expansion enables a seamless, single-site pathway from early protein discovery through CMC development to Phase 1/2 GMP manufacturing for complex biologics.
Philip Wills, Chief Commercial Officer of the Cell & Gene Therapy Division at Catalent, reflects on how the gene therapy industry is evolving from early scientific breakthroughs to commercial maturity.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.